<bill session="118" type="h" number="5074" updated="2025-05-27T14:14:31Z">
  <state datetime="2024-03-06">REPORTED</state>
  <status>
    <unknown datetime="2024-03-06"/>
  </status>
  <introduced datetime="2023-07-28"/>
  <titles>
    <title type="display">Kidney PATIENT Act of 2023</title>
    <title type="short" as="introduced">Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023</title>
    <title type="short" as="introduced">Kidney PATIENT Act of 2023</title>
    <title type="official" as="introduced">To amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.</title>
  </titles>
  <sponsor bioguide_id="C001103"/>
  <cosponsors>
    <cosponsor bioguide_id="A000380" joined="2024-12-17"/>
    <cosponsor bioguide_id="A000375" joined="2023-12-19"/>
    <cosponsor bioguide_id="B001275" joined="2024-03-20"/>
    <cosponsor bioguide_id="C001125" joined="2024-09-17"/>
    <cosponsor bioguide_id="C001067" joined="2023-11-08"/>
    <cosponsor bioguide_id="C001130" joined="2024-07-30"/>
    <cosponsor bioguide_id="C001063" joined="2023-12-04"/>
    <cosponsor bioguide_id="C001114" joined="2024-12-03"/>
    <cosponsor bioguide_id="D000096" joined="2023-11-17"/>
    <cosponsor bioguide_id="D000230" joined="2023-10-06"/>
    <cosponsor bioguide_id="E000299" joined="2024-09-24"/>
    <cosponsor bioguide_id="E000297" joined="2024-09-24"/>
    <cosponsor bioguide_id="F000465" joined="2023-11-17"/>
    <cosponsor bioguide_id="F000480" joined="2024-07-30"/>
    <cosponsor bioguide_id="G000581" joined="2024-10-18"/>
    <cosponsor bioguide_id="H001081" joined="2024-11-14"/>
    <cosponsor bioguide_id="H001066" joined="2024-10-18"/>
    <cosponsor bioguide_id="H001067" joined="2024-12-11"/>
    <cosponsor bioguide_id="J000309" joined="2024-07-22"/>
    <cosponsor bioguide_id="J000288" joined="2024-01-29"/>
    <cosponsor bioguide_id="J000302" joined="2023-11-13"/>
    <cosponsor bioguide_id="K000375" joined="2024-07-09"/>
    <cosponsor bioguide_id="K000397" joined="2024-11-05"/>
    <cosponsor bioguide_id="K000382" joined="2023-07-28"/>
    <cosponsor bioguide_id="L000562" joined="2024-07-11"/>
    <cosponsor bioguide_id="M001137" joined="2024-10-18"/>
    <cosponsor bioguide_id="M001205" joined="2023-07-28"/>
    <cosponsor bioguide_id="M001213" joined="2023-11-30"/>
    <cosponsor bioguide_id="M001196" joined="2024-07-24"/>
    <cosponsor bioguide_id="P000619" joined="2024-10-11"/>
    <cosponsor bioguide_id="P000597" joined="2024-11-14"/>
    <cosponsor bioguide_id="R000579" joined="2024-10-04"/>
    <cosponsor bioguide_id="S001221" joined="2024-10-08"/>
    <cosponsor bioguide_id="S001185" joined="2023-07-28"/>
    <cosponsor bioguide_id="S001135" joined="2024-09-09"/>
    <cosponsor bioguide_id="S001201" joined="2024-10-04"/>
    <cosponsor bioguide_id="S001193" joined="2024-09-10"/>
    <cosponsor bioguide_id="S001223" joined="2024-10-11"/>
    <cosponsor bioguide_id="S001156" joined="2024-11-21"/>
    <cosponsor bioguide_id="T000460" joined="2024-08-30"/>
    <cosponsor bioguide_id="T000486" joined="2024-10-25"/>
    <cosponsor bioguide_id="V000129" joined="2024-09-03"/>
    <cosponsor bioguide_id="V000136" joined="2024-10-04"/>
    <cosponsor bioguide_id="V000081" joined="2024-10-18"/>
    <cosponsor bioguide_id="W000187" joined="2024-10-01"/>
  </cosponsors>
  <actions>
    <action datetime="2023-07-28">
      <text>Introduced in House</text>
    </action>
    <action datetime="2023-07-28" state="REFERRED">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2023-07-28">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2023-08-04">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
    <action datetime="2024-03-06">
      <text>Committee Consideration and Mark-up Session Held</text>
    </action>
    <action datetime="2024-03-06">
      <text>Committee Consideration and Mark-up Session Held</text>
    </action>
    <action datetime="2024-03-06" state="REPORTED">
      <text>Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 41 - 1.</text>
    </action>
    <action datetime="2024-03-12">
      <text>Subcommittee Consideration and Mark-up Session Held</text>
    </action>
    <action datetime="2024-03-12">
      <text>Forwarded by Subcommittee to Full Committee by the Yeas and Nays: 16 - 10.</text>
    </action>
    <action datetime="2024-03-20">
      <text>Committee Consideration and Mark-up Session Held</text>
    </action>
    <action datetime="2024-03-20">
      <text>Ordered to be Reported (Amended) by the Yeas and Nays: 37 - 10.</text>
    </action>
    <action datetime="2024-06-11">
      <text>Reported (Amended) by the Committee on Ways and Means. H. Rept. 118-548, Part I.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSWM" name="House Ways and Means" subcommittee="" activity="Reported By, Markup By, Referred To"/>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Markup By, Referred To"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Reporting, Markup, Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Digestive and metabolic diseases"/>
    <term name="Health care costs and insurance"/>
    <term name="Medicare"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2024-03-25T20:26:46Z" status="Introduced in House">Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 or the Kidney PATIENT Act of 2023

This bill delays a change to the payment methodology under Medicare for oral drugs that are used to treat end-stage renal disease (ESRD).

Under current regulations, beginning January 1, 2025, the Centers for Medicare &amp; Medicaid Services will incorporate payments for oral-only ESRD drugs into the ESRD prospective payment system rather than issuing separate payments to ESRD facilities. The bill delays implementation of this policy until January 1, 2033, or until an approved intravenous drug is available, whichever is earlier.</summary>
  <committee-reports>
    <report>H. Rept. 118-548</report>
  </committee-reports>
</bill>
